- Home
- CPT vs PODD Comparison
CPT vs PODD Comparison
Compare CPT & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CPT | PODD |
|---|---|---|
| Founded | 1993 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3B | 10.2B |
| IPO Year | 1995 | 2007 |
Fundamental Metrics
Financial Performance| Metric | CPT | PODD |
|---|---|---|
| Price | $99.90 | $145.63 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 24 | 26 |
| Target Price | $111.28 | ★ $167.17 |
| AVG Volume (30 Days) | 776.6K | ★ 1.3M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | ★ 4.09% | N/A |
| EPS Growth | ★ 136.00 | N/A |
| EPS | 0.59 | ★ 4.69 |
| Revenue | $12,967,000.00 | ★ $2,708,100,000.00 |
| Revenue This Year | N/A | $21.37 |
| Revenue Next Year | $0.82 | $13.57 |
| P/E Ratio | $177.08 | ★ $35.19 |
| Revenue Growth | ★ 81.69 | 30.73 |
| 52 Week Low | $95.30 | $126.40 |
| 52 Week High | $119.81 | $354.88 |
Technical Indicators
Market Signals| Indicator | CPT | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 47.51 | 48.57 |
| Support Level | $99.36 | $140.85 |
| Resistance Level | $103.71 | $153.33 |
| Average True Range (ATR) | 2.36 | 6.80 |
| MACD | 0.27 | 0.50 |
| Stochastic Oscillator | 28.07 | 16.56 |
Price Performance
Historical ComparisonAbout CPT Camden Property Trust
Camden Property Trust is a real estate investment trust engaged in the ownership, management, development, reposition, redevelopment, acquisition, and construction of multifamily apartment communities. It owned interests in, operated, or developing nearly 175 multifamily properties comprised of nearly 59,921 apartment homes across the United States.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.